Vincenzo Pavone

List of Publications by Year in Descending Order

187 papers	6,484 citations	41 h-index	70 g-index
195 ext. papers	6,890 ext. citations	5.8 avg, IF	5.27 L-index

#	Paper	IF	Citations
187	Oxidative dehalogenation of trichlorophenol catalyzed by a promiscuous artificial heme-enzyme.. *RSC Advances*, **2022**, 12, 12947-12956	3.7	2
186	Highly Selective Indole Oxidation Catalyzed by a Mn-Containing Artificial Mini-Enzyme. *ACS Catalysis*, **2021**, 11, 9407-9417	13.1	7
185	Pharmacokinetics of the Urokinase Receptor-Derived Peptide UPARANT After Single and Multiple Doses Administration in Rats. *European Journal of Drug Metabolism and Pharmacokinetics*, **2021**, 46, 119-128	2.7	
184	Histidine orientation in artificial peroxidase regioisomers as determined by paramagnetic NMR shifts. *Chemical Communications*, **2021**, 57, 990-993	5.8	5
183	Clickable artificial heme-peroxidases for the development of functional nanomaterials. *Biotechnology and Applied Biochemistry*, **2020**, 67, 549-562	2.8	6
182	COVID-19 and pneumonia: a role for the uPA/uPAR system. *Drug Discovery Today*, **2020**, 25, 1528-1534	8.8	30
181	Use of an Artificial Miniaturized Enzyme in Hydrogen Peroxide Detection by Chemiluminescence. *Sensors*, **2020**, 20,	3.8	9
180	Mimochrome, a metalloporphyrin-based catalytic Swiss knife *Biotechnology and Applied Biochemistry*, **2020**, 67, 495-515	2.8	16
179	Gaining insight on mitigation of rubeosis iridis by UPARANT in a mouse model associated with proliferative retinopathy. *Journal of Molecular Medicine*, **2020**, 98, 1629-1638	5.5	1
178	Oocyte provision as a (quasi) social market: Insights from Spain. *Social Science and Medicine*, **2019**, 234, 112381	5.1	7
177	The uPAR System as a Potential Therapeutic Target in the Diseased Eye. *Cells*, **2019**, 8,	7.9	7
176	The urokinase-type plasminogen activator system as drug target in retinitis pigmentosa: New pre-clinical evidence in the rd10 mouse model. *Journal of Cellular and Molecular Medicine*, **2019**, 23, 5176-5192	5.6	11
175	Engineering Metalloprotein Functions in Designed and Native Scaffolds. *Trends in Biochemical Sciences*, **2019**, 44, 1022-1040	10.3	50
174	UPARANT is an effective antiangiogenic agent in a mouse model of rubeosis iridis. *Journal of Molecular Medicine*, **2019**, 97, 1273-1283	5.5	3
173	Inhibiting the urokinase-type plasminogen activator receptor system recovers STZ-induced diabetic nephropathy. *Journal of Cellular and Molecular Medicine*, **2019**, 23, 1034-1049	5.6	14
172	Exploring the role of unnatural amino acids in antimicrobial peptides. *Scientific Reports*, **2018**, 8, 8888	4.9	46
171	Enhancement of Peroxidase Activity in Artificial Mimochrome VI Catalysts through Rational Design. *ChemBioChem*, **2018**, 19, 1823-1826	3.8	27

170	Selecting What? Pre-implantation Genetic Diagnosis and Screening Trajectories in Spain **2018**, 123-148		
169	Mn-Mimochrome VIa: An Artificial Metalloenzyme With Peroxygenase Activity. *Frontiers in Chemistry*, **2018**, 6, 590	5	18
168	Artificial Heme Enzymes for the Construction of Gold-Based Biomaterials. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	10
167	Hydrogen evolution from water catalyzed by cobalt-mimochrome VI*a, a synthetic mini-protein. *Chemical Science*, **2018**, 9, 8582-8589	9.4	42
166	Inflammation and N-formyl peptide receptors mediate the angiogenic activity of human vitreous humour in proliferative diabetic retinopathy. *Diabetologia*, **2017**, 60, 719-728	10.3	26
165	Preclinical evaluation of the urokinase receptor-derived peptide UPARANT as an anti-inflammatory drug. *Inflammation Research*, **2017**, 66, 701-709	7.2	10
164	A De Novo Heterodimeric Due Ferri Protein Minimizes the Release of Reactive Intermediates in Dioxygen-Dependent Oxidation. *Angewandte Chemie - International Edition*, **2017**, 56, 15580-15583	16.4	25
163	A De Novo Heterodimeric Due Ferri Protein Minimizes the Release of Reactive Intermediates in Dioxygen-Dependent Oxidation. *Angewandte Chemie*, **2017**, 129, 15786-15786	3.6	3
162	Diabetic Retinopathy in the Spontaneously Diabetic Torii Rat: Pathogenetic Mechanisms and Preventive Efficacy of Inhibiting the Urokinase-Type Plasminogen Activator Receptor System. *Journal of Diabetes Research*, **2017**, 2017, 2904150	3.9	12
161	The Urokinase Receptor-Derived Peptide UPARANT Recovers Dysfunctional Electroretinogram and Blood-Retinal Barrier Leakage in a Rat Model of Diabetes **2017**, 58, 3138-3148		13
160	Nano-in-Nano Approach for Enzyme Immobilization Based on Block Copolymers. *ACS Applied Materials & Interfaces*, **2017**, 9, 29318-29327	9.5	18
159	A Quartz Crystal Microbalance Immunosensor for Stem Cell Selection and Extraction. *Sensors*, **2017**, 17,	3.8	14
158	Bio-Identification, Value Creation and the Reproductive Bioeconomy: Insights from the Reprogenetics Sector in Spain **2017**, 129-159		1
157	A Systemic Approach to Security: Beyond the Tradeoff between Security and Liberty. *Democracy and Security*, **2016**, 12, 225-246	0.4	13
156	Molecular Mechanisms Mediating Antiangiogenic Action of the Urokinase Receptor-Derived Peptide UPARANT in Human Retinal Endothelial Cells **2016**, 57, 5723-5735		17
155	The Urokinase Receptor-Derived Peptide UPARANT Mitigates Angiogenesis in a Mouse Model of Laser-Induced Choroidal Neovascularization **2016**, 57, 2600-2611		20
154	An artificial heme-enzyme with enhanced catalytic activity: evolution, functional screening and structural characterization. *Organic and Biomolecular Chemistry*, **2015**, 13, 4859-68	3.9	31
153	Branched porphyrins as functional scaffolds for multisite bioconjugation. *Biotechnology and Applied Biochemistry*, **2015**, 62, 383-92	2.8	3

152	The Bioeconomy as Political Project: A Polanyian Analysis. *Science Technology and Human Values*, **2015**, 40, 302-337	2.5	81
151	Artificial Diiron Enzymes with a De Novo Designed Four-Helix Bundle Structure. *European Journal of Inorganic Chemistry*, **2015**, 2015, 3371-3390	2.3	50
150	Cisgenics as emerging bio-objects: bio-objectification and bio-identification in agrobiotech innovation. *New Genetics and Society*, **2015**, 34, 52-71	1.9	13
149	UPARANT: a urokinase receptor-derived peptide inhibitor of VEGF-driven angiogenesis with enhanced stability and in vitro and in vivo potency. *Molecular Cancer Therapeutics*, **2014**, 13, 1092-104	6.1	35
148	Artificial heme-proteins: determination of axial ligand orientations through paramagnetic NMR shifts. *Chemical Communications*, **2014**, 50, 3852-5	5.8	14
147	Crystal structure of an amphiphilic foldamer reveals a 48-mer assembly comprising a hollow truncated octahedron. *Nature Communications*, **2014**, 5, 3581	17.4	11
146	Evaluation of the oligosaccharide composition of commercial follicle stimulating hormone preparations. *Electrophoresis*, **2013**, 34, 2394-406	3.6	16
145	Democratising research evaluation: Achieving greater public engagement with bibliometrics-informed peer review. *Science and Public Policy*, **2013**, 40, 563-575	1.8	24
144	Bio-objects' political capacity: a research agenda. *Croatian Medical Journal*, **2013**, 54, 206-11	1.6	6
143	A urokinase receptor-derived peptide inhibiting VEGF-dependent directional migration and vascular sprouting. *Molecular Cancer Therapeutics*, **2013**, 12, 1981-93	6.1	29
142	De novo design, synthesis and characterisation of MP3, a new catalytic four-helix bundle hemeprotein. *Chemistry - A European Journal*, **2012**, 18, 15960-71	4.8	28
141	Single amino acid substitutions in the chemotactic sequence of urokinase receptor modulate cell migration and invasion. *PLoS ONE*, **2012**, 7, e44806	3.7	24
140	Beyond the Geneticization Thesis: The Political Economy of PGD/PGS in Spain. *Science Technology and Human Values*, **2012**, 37, 235-261	2.5	21
139	Public assessment of new surveillance-oriented security technologies: Beyond the trade-off between privacy and security. *Public Understanding of Science*, **2012**, 21, 556-72	3.1	48
138	From risk assessment to in-context trajectory evaluation - GMOs and their social implications. *Environmental Sciences Europe*, **2011**, 23,		22
137	A heme-peptide metalloenzyme mimetic with natural peroxidase-like activity. *Chemistry - A European Journal*, **2011**, 17, 4444-53	4.8	62
136	Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity. *FASEB Journal*, **2011**, 25, 1230-43	0.9	16
135	Redox and electrocatalytic properties of mimochrome VI, a synthetic heme peptide adsorbed on gold. *Langmuir*, **2010**, 26, 17831-5	4	26

134	Spectroscopic and metal-binding properties of DF3: an artificial protein able to accommodate different metal ions. *Journal of Biological Inorganic Chemistry*, **2010**, 15, 717-28	3.7	24
133	A FRET-based biosensor for NO detection. *Journal of Inorganic Biochemistry*, **2010**, 104, 619-24	4.2	22
132	The soluble form of urokinase receptor promotes angiogenesis through its Ser-Arg-Ser-Arg-Tyr chemotactic sequence. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 2789-99	15.4	34
131	Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis. *Molecular Cancer Therapeutics*, **2009**, 8, 2708-17	6.1	45
130	Conformation of linear homo-oligoprolines. *International Journal of Peptide and Protein Research*, **2009**, 20, 312-319		7
129	Modified calmodulin calcium binding domain III.. *International Journal of Peptide and Protein Research*, **2009**, 23, 454-461		6
128	An artificial di-iron oxo-protein with phenol oxidase activity. *Nature Chemical Biology*, **2009**, 5, 882-4	11.7	152
127	What do civil society organisations expect from participation in science? Lessons from Germany and Spain on the issue of GMOs. *Science and Public Policy*, **2009**, 36, 287-299	1.8	22
126	An urokinase receptor antagonist that inhibits cell migration by blocking the formyl peptide receptor. *FEBS Letters*, **2008**, 582, 1141-6	3.8	33
125	Diiron-containing metalloproteins: Developing functional models. *Comptes Rendus Chimie*, **2007**, 10, 703-720	2.7	39
124	From intergovernmental to global: UNESCO response to globalization. *Review of International Organizations*, **2007**, 2, 77-95	5.5	12
123	Hemoprotein Models Based on a Covalent Helix-Heme-Helix Sandwich: 1. Design, Synthesis, and Characterization. *Chemistry - A European Journal*, **2006**, 3, 340-349	4.8	57
122	Hemoprotein Models Based on a Covalent Helix-Heme-Helix Sandwich: 2. Structural Characterization of CoIII Mimochrome I and Isomers. *Chemistry - A European Journal*, **2006**, 3, 350-362	4.8	41
121	Critical role of the N-loop and beta1-strand hydrophobic clusters of RANTES-derived peptides in anti-HIV activity. *Biochemical and Biophysical Research Communications*, **2006**, 351, 664-8	3.4	14
120	Artificial diiron proteins: from structure to function. *Biopolymers*, **2005**, 80, 264-78	2.2	82
119	Artificial di-iron proteins: solution characterization of four helix bundles containing two distinct types of inter-helical loops. *Journal of Biological Inorganic Chemistry*, **2005**, 10, 539-49	3.7	28
118	Miniaturized heme proteins: crystal structure of Co(III)-mimochrome IV. *Journal of Biological Inorganic Chemistry*, **2004**, 9, 1017-27	3.7	35
117	Preorganization of molecular binding sites in designed diiron proteins. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 3772-7	11.5	67

116	Design of a new mimochrome with unique topology. *Chemistry - A European Journal*, **2003**, 9, 5643-54	4.8	38
115	Sliding helix and change of coordination geometry in a model di-MnII protein. *Angewandte Chemie - International Edition*, **2003**, 42, 417-20	16.4	48
114	Conformational and coordination properties of a peptide containing the novel ╫bis(2-pyridyl)glycine amino acid. *Dalton Transactions*, **2003**, 787-792	4.3	10
113	Developing synthetic hemoprotein mimetics: Design, synthesis and characterization of heme-peptide conjugates **2002**, 91-93		
112	A novel class of Calmodulin mimetics: De Novo designed proteins in molecular recognition **2002**, 94-96		
111	Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES. *Nature Structural Biology*, **2001**, 8, 611-5		48
110	Peptide-based heme-protein models. *Chemical Reviews*, **2001**, 101, 3165-89	68.1	163
109	Toward the de novo design of a catalytically active helix bundle: a substrate-accessible carboxylate-bridged dinuclear metal center. *Journal of the American Chemical Society*, **2001**, 123, 12749-57	16.4	92
108	The crystal structure of Afc-containing peptides. *Biopolymers*, **2000**, 53, 150-60	2.2	12
107	Conformational behavior of C alpha,alpha-diphenyl glycine: extended conformation in tripeptides containing consecutive D phi G residues. *Biopolymers*, **2000**, 53, 161-8	2.2	9
106	The crystal structure of a Dcp-containing peptide. *Biopolymers*, **2000**, 53, 182-8	2.2	12
105	Miniaturized metalloproteins: application to iron-sulfur proteins. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 11922-7	11.5	57
104	Retrostructural analysis of metalloproteins: application to the design of a minimal model for diiron proteins. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 6298-305	11.5	197
103	The crystal structure of alpha-thrombin-hirunorm IV complex reveals a novel specificity site recognition mode. *Protein Science*, **1999**, 8, 91-5	6.3	6
102	Crystallization and preliminary X-ray diffraction studies of the carboxylesterase EST2 from Alicyclobacillus acidocaldarius. *Acta Crystallographica Section D: Biological Crystallography*, **1999**, 55, 1348-9		13
101	From natural to synthetic multisite thrombin inhibitors. *Biopolymers*, **1999**, 51, 19-39	2.2	20
100	De novo design and structural characterization of proteins and metalloproteins. *Annual Review of Biochemistry*, **1999**, 68, 779-819	29.1	529
99	Miniaturized hemoproteins: design, synthesis and characterization of mimochrome II. *Inorganica Chimica Acta*, **1998**, 275-276, 301-313	2.7	16

98	Miniaturized hemoproteins. *Biopolymers*, **1998**, 47, 5-22	2.2	27
97	Conformational behaviour of C□diphenylglycine: folded vs. extended structures in D?G-containing tripeptides. *Journal of Peptide Science*, **1998**, 4, 21-32	2.1	18
96	Hemoprotein models based on a covalent helix-heme-helix sandwich. 3. Coordination properties, reactivity and catalytic application of Fe(III)- and Fe(II)-mimochrome I. *Journal of Biological Inorganic Chemistry*, **1998**, 3, 671-681	3.7	26
95	A novel super-potent neurokinin A receptor antagonist containing dehydroalanine. *Bioorganic and Medicinal Chemistry Letters*, **1998**, 8, 1153-6	2.9	9
94	Neuronorm is a potent and water soluble neurokinin A receptor antagonist. *Bioorganic and Medicinal Chemistry Letters*, **1998**, 8, 1735-40	2.9	1
93	Hirunorms are true hirudin mimetics. The crystal structure of human alpha-thrombin-hirunorm V complex. *Protein Science*, **1998**, 7, 243-53	6.3	12
92	A Novel Rigid □Turn Molecular Scaffold. *Journal of the American Chemical Society*, **1998**, 120, 5879-5886	16.4	18
91	Miniaturized hemoproteins **1998**, 47, 5		2
90	In vitro activities of A-gliadin-related synthetic peptides: damaging effect on the atrophic coeliac mucosa and activation of mucosal immune response in the treated coeliac mucosa. *Scandinavian Journal of Gastroenterology*, **1996**, 31, 247-53	2.4	92
89	Bicyclic peptides as type I/type II beta-turn scaffolds. *Biopolymers*, **1996**, 40, 505-18	2.2	10
88	Rational design of true hirudin mimetics: synthesis and characterization of multisite-directed alpha-thrombin inhibitors. *Journal of Medicinal Chemistry*, **1996**, 39, 2008-17	8.3	20
87	Crystal and Molecular Structure of the [6-Deoxy-6-[(2-(4-imidazolyl)ethyl)amino]-cyclomaltoheptaose]copper(II) Ternary Complex with L-Tryptophanate. Role of Weak Forces in the Chiral Recognition Process Assisted by a Metallocyclodextrin. *Inorganic Chemistry*, **1996**, 35, 4497-4504	5.1	24
86	A review of the design, synthesis and biological activity of the bicyclic hexapeptide tachykinin NK2 antagonist MEN 10627. *Regulatory Peptides*, **1996**, 65, 55-9		16
85	Solvent-mediated conformational transition in □alanine containing cyclic peptides. VIII **1996**, 38, 693-703		15
84	Discovering protein secondary structures: Classification and description of isolated □turns **1996**, 38, 705-721		99
83	A Modified Cyclodextrin with a Fully Encapsulated Dansyl Group: Self-Inclusion in the Solid State and in Solution. *Chemistry - A European Journal*, **1996**, 2, 373-381	4.8	93
82	Unusual conformational preferences of beta-alanine containing cyclic peptides. VII. *Biopolymers*, **1996**, 38, 683-91	2.2	14
81	Discovering protein secondary structures: classification and description of isolated alpha-turns. *Biopolymers*, **1996**, 38, 705-21	2.2	23

80	Conformational rigidity versus flexibility in a novel peptidic neurokinin A receptor antagonist. *Journal of Peptide Science*, **1995**, 1, 236-40	2.1	18
79	Conformational behaviour of a cyclolinopeptide A analogue: two-dimensional NMR study of cyclo(Pro1-Pro-Phe-Phe-Ac6c-Ile-ala-Val8). *Journal of Peptide Science*, **1995**, 1, 330-40	2.1	9
78	Design and structure of a novel Neurokinin A receptor antagonist cyclo(-Met1-Asp2-Trp3-Phe4-Dap5-Leu6-)cyclo(2→5). *Journal of the Chemical Society Perkin Transactions II*, **1995**, 987-993		24
77	Specific interaction between cyclophilin and cyclic peptides. *Biopolymers*, **1995**, 36, 273-81	2.2	17
76	Defect peptide chemistry: perturbations in the structure of a homopentapeptide induced by a guest residue interrupting side-chain regularity. *Biopolymers*, **1994**, 34, 1409-18	2.2	15
75	Beta-alanine containing cyclic peptides with predetermined turned structure. V. *Biopolymers*, **1994**, 34, 1505-15	2.2	18
74	Beta-alanine containing cyclic peptides with turned structure: the "pseudo type II beta-turn." VI. *Biopolymers*, **1994**, 34, 1517-26	2.2	19
73	Mixed conformation in C alpha, alpha-disubstituted tripeptides: x-ray crystal structures of Z-Aib-Dph-Gly-OMe and Bz-Dph-Dph-Gly-OMe. *Biopolymers*, **1994**, 34, 1595-604	2.2	16
72	Conformational studies on peptides as enzyme inhibitors: chymotrypsin inhibitors using Bowman□Birk type as models. *Journal of the Chemical Society Perkin Transactions II*, **1994**, 1047-1053		10
71	Influence of lipophilicity on the biological activity of cyclic pseudopeptide NK-2 receptor antagonists. *Journal of Medicinal Chemistry*, **1994**, 37, 3630-8	8.3	14
70	Noncoded residues as building blocks in the design of specific secondary structures: symmetrically disubstituted glycines and beta-alanine. *Biopolymers*, **1993**, 33, 1037-49	2.2	59
69	Pt(II) complexes of amino acids and peptides III. X-ray diffraction study of [Cl(Ph3P)Pt(H-Aib-O)]. *Inorganica Chimica Acta*, **1993**, 204, 87-92	2.7	13
68	Molecular dynamics simulation in vacuo and in solution of [Aib5,6-D-Ala8] cyclolinopeptide A: a conformational and comparative study. *Journal of Biomolecular Structure and Dynamics*, **1992**, 9, 1045-60	3.6	13
67	Conformation for a beta-cyclodextrin monosubstituted with a cyclic dipeptide. *Proceedings of the National Academy of Sciences of the United States of America*, **1992**, 89, 7218-21	11.5	40
66	A helical Dpg homo-peptide. *Journal of the Chemical Society Perkin Transactions II*, **1992**, 523		20
65	First observation of a helical peptide containing chiral □monosubstituted residues without a preferred screw sense. *Journal of the Chemical Society Perkin Transactions II*, **1992**, 971-977		6
64	□Alanine and □bends. X-Ray diffraction structures of three linear oligopeptides. *Journal of the Chemical Society Perkin Transactions II*, **1992**, 1233-1237		30
63	Bioactive peptides: x-ray and NMR conformational study of [Aib5,6-D-Ala8]cyclolinopeptide A. *Journal of the American Chemical Society*, **1992**, 114, 8277-8283	16.4	33

62	Structural characterization of the .beta.-bend ribbon spiral: crystallographic analysis of two long (L-Pro-Aib)n sequential peptides. *Journal of the American Chemical Society*, **1992**, 114, 6273-6278	16.4	100
61	Pt(II) complexes of amino acids and peptides II. Structural analysis of trans-[Cl2-Pt-(H-Aib-OH)2n] and trans-[Pt-(H-Aib-O)2]. *Inorganica Chimica Acta*, **1992**, 196, 241-246	2.7	9
60	Preferred conformation of the terminally blocked (Aib)10 homo-oligopeptide: A long, regular 310-helix. *Biopolymers*, **1991**, 31, 129-138	2.2	106
59	Crystal-state conformation of homo-oligomers of □-aminoisobutyric acid: Molecular and crystal structure of pBrBz-(Aib)6-OMe. *Structural Chemistry*, **1991**, 2, 523-527	1.8	19
58	The polypeptide 310-helix **1991**, 302-304		1
57	Helical structures in peptides **1991**, 454-455		
56	Structure of clathridine Zn-complex, a metabolite of the marine sponge Clathrina clathrus. *Tetrahedron*, **1990**, 46, 4387-4392	2.4	36
55	Stereochemical behavior of acyclic peptide-cation complexes. *Biopolymers*, **1990**, 30, 197-204	2.2	2
54	Bicyclic peptides: solid state conformation of cyclo(Glu-Leu-Pro-Gly-Lys-Leu-Pro-Gly)cyclo(1gamma-5epsilon)Gly. *Biopolymers*, **1990**, 30, 509-16	2.2	3
53	Critical Main-Chain Length for Conformational Conversion From 3(10)-Helix to □-Helix in Polypeptides. *Journal of Biomolecular Structure and Dynamics*, **1990**, 7, 1321-1331	3.6	77
52	Linear oligopeptides. Part 227. X-Ray crystal and molecular structures of two □-helix-forming (Aib-L-Ala)sequential oligopeptides, pBrBz-(Aib-L-Ala)5-OMe and pBrBz-(Aib-L-Ala)6-OMe. *Journal of the Chemical Society Perkin Transactions II*, **1990**, 1829-1837		38
51	Crystal structure of two retro-inverso sweeteners. *Journal of the American Chemical Society*, **1990**, 112, 8909-8912	16.4	24
50	The longest, regular polypeptide 3(10) helix at atomic resolution. *Journal of Molecular Biology*, **1990** , 214, 633-5	6.5	80
49	Structure-toxicity relationships in the amatoxin series. Synthesis of S-deoxy[gamma(R)-hydroxy-Ile3]-amaninamide, its crystal and molecular structure and inhibitory efficiency. *International Journal of Peptide and Protein Research*, **1989**, 34, 222-8		24
48	Regularly alternating L,D-peptides. I. The double-stranded left-handed antiparallel beta-helix in the structure of Boc-(L-Val-D-Val)4-OMe. *Biopolymers*, **1989**, 28, 193-201	2.2	27
47	Regularly alternating L,D-peptides. II. The double-stranded right-handed antiparallel beta-helix in the structure of t-Boc-(L-Phe-D-Phe)4-OMe. *Biopolymers*, **1989**, 28, 203-14	2.2	38
46	Regularly alternating L,D-peptides. III. Hexacyclic peptides from valine or phenylalanine. *Biopolymers*, **1989**, 28, 215-23	2.2	47
45	Bioactive peptides: solid-state and solution conformation of cyclolinopeptide A. *Journal of the American Chemical Society*, **1989**, 111, 9089-9098	16.4	73

44	Structural versatility of peptides containing C alpha, alpha-dialkylated glycines: conformational energy computations, i.r. absorption and 1H n.m.r. analysis of 1-aminocyclopropane-1-carboxylic acid homopeptides. *International Journal of Biological Macromolecules*, **1989**, 11, 345-52	7.9	30
43	Structural versatility of peptides containing C alpha, alpha-dialkylated glycines. An X-ray diffraction study of six 1-aminocyclopropane-1-carboxylic acid rich peptides. *International Journal of Biological Macromolecules*, **1989**, 11, 353-60	7.9	50
42	Preparation of All the Four Diastereomers of b-Phenylcysteine Methyl Ester through Chromatographic Optical Resolution of the 2,2-Dimethylthiazolidine Derivatives. *Heterocycles*, **1989**, 28, 589	0.8	10
41	Pt(II) complexes of amino acids and peptides. I. Structural analysis of trans-[Cl2Pt(L-HAlaOH)2]. *Inorganica Chimica Acta*, **1988**, 153, 171-174	2.7	12
40	Structural versatility of peptides from C.alpha.,.alpha.-dialkylated glycines. A conformational energy computation and x-ray diffraction study of homopeptides from 1-aminocyclohexane-1-carboxylic acid1. *Macromolecules*, **1988**, 21, 2064-2070	5.5	36
39	Structural versatility of peptides from C.alpha.,.alpha.-dialkylated glycines. An infrared absorption and 1H nuclear magnetic resonance study of homopeptides from 1-aminocyclohexane-1-carboxylic acid1. *Macromolecules*, **1988**, 21, 2071-2074	5.5	25
38	Structural versatility of peptides from C□dialkylated glycines: a conformational energy calculation and X-ray diffraction study of homopeptides from 1-aminocyclopentane-1-carboxylic acid. *International Journal of Biological Macromolecules*, **1988**, 10, 292-299	7.9	43
37	Structural versatility of peptides from C□dialkylated glycines: an infrared absorption and 1H n.m.r. study of homopeptides from 1-aminocyclopentane-1-carboxylic acid. *International Journal of Biological Macromolecules*, **1988**, 10, 300-304	7.9	35
36	On □-hairpin classification. *International Journal of Biological Macromolecules*, **1988**, 10, 238-240	7.9	6
35	Long, chiral polypeptide 3(10)-helices at atomic resolution. *Journal of Biomolecular Structure and Dynamics*, **1988**, 5, 803-17	3.6	36
34	Long polypeptide 3(10)-helices at atomic resolution. *Proceedings of the National Academy of Sciences of the United States of America*, **1986**, 83, 1988-92	11.5	61
33	A novel peptide conformation: First unequivocal observation of the oxy-analog of a □-bend. *Biopolymers*, **1986**, 25, 2237-2253	2.2	31
32	Cyclic peptide metal salt adducts. II. crystal structure of the silver nitrate cyclosarcosylsarcosine 2:1 adduct. *Inorganica Chimica Acta*, **1986**, 116, 31-35	2.7	11
31	Cyclic peptide-metal salt adducts. I. crystal structure of the hexaquocopper(II) perchlorate cyclosarcosylsarcosine 1:2 adducts. *Inorganica Chimica Acta*, **1986**, 123, 155-159	2.7	5
30	Stereostructure and formation mechanisn of a new substituted benzofuran from phomenone.. *Tetrahedron*, **1986**, 42, 4493-4498	2.4	4
29	Linear oligopeptides. Part 147. Chemical and crystallographic study of the reaction between benzyloxycarbonyl chloride and □-aminoisobutyric acid. *Journal of the Chemical Society Perkin Transactions II*, **1986**, 1371-1376		27
28	A long, regular polypeptide 310-helix. *Macromolecules*, **1986**, 19, 472-479	5.5	85
27	Preferred structures of constrained peptides from achiral □-dialkyiated glycyl residues with acyclic side chains. *Journal of Biosciences*, **1985**, 8, 253-262	2.3	13

26	Conformational behavior of dialkylated peptides. *Biopolymers*, **1985**, 24, 1759-1767	2.2	72
25	Molecular structure of peptaibol antibiotics: solution conformation and crystal structure of the octapeptide corresponding to the 2-9 sequence of emerimicins III and IV. *Journal of Biomolecular Structure and Dynamics*, **1985**, 3, 585-98	3.6	25
24	Linear oligopeptides effect of lengthening of the main chain by one tetrahedral carbon atom in the -Aib-l-Ala- sequence: a solid-state conformational analysis of segments of polypeptide antibiotics. *International Journal of Biological Macromolecules*, **1985**, 7, 81-88	7.9	25
23	Linear oligopeptides: peptaibol antibiotics preferred conformation of the 2 segment of emerimicins III and IV and all related short sequences. *International Journal of Biological Macromolecules*, **1985**, 7, 357-362	7.9	5
22	Conformation of pleionomers of .alpha.-aminoisobutyric acid. *Macromolecules*, **1985**, 18, 895-902	5.5	178
21	Folded and extended structures of homooligopeptides from .alpha.,.alpha.-dialkylated glycines. A conformational energy computation and x-ray diffraction study. *Journal of the American Chemical Society*, **1984**, 106, 8146-8152	16.4	87
20	Folded and extended structures of homooligopeptides from .alpha.,.alpha.-dialkylated .alpha.-amino acids. An infrared absorption and proton nuclear magnetic resonance study. *Journal of the American Chemical Society*, **1984**, 106, 8152-8156	16.4	63
19	Protected 1-3 segment of the peptaibol antibiotics alamethicin and hypelcin. Solid-state and solution study of a stereochemically constrained linear peptide. *International Journal of Peptide and Protein Research*, **1983**, 22, 385-97		10
18	Bioorganic stereochemistry. A study of the peptide oxazolones from Z-(Aib)n-OH (n = 2-4) in the solid state. *International Journal of Peptide and Protein Research*, **1983**, 22, 603-10		18
17	Preferred conformations of peptides containing disubstituted amino acids. *Biopolymers*, **1983**, 22, 205-215	2.2	238
16	Solid-state geometry and conformation of linear, diastereoisomeric oligoprolines. *Biopolymers*, **1983**, 22, 305-317	2.2	71
15	Structure and conformation of regularly alternating L,D linear peptides. *Biopolymers*, **1983**, 22, 323-325	2.2	4
14	Peptaibol antibiotics: Conformational preferences of synthetic emerimicin fragments. *Biopolymers*, **1983**, 22, 1335-1356	2.2	25
13	First observation of a beta-turn conformation fused with the oxy-analogue of an alpha-turn: the molecular structure of a model peptide of the C-terminal part of gramicidin A. *Biochemical and Biophysical Research Communications*, **1983**, 112, 1056-60	3.4	4
12	Peptaibol antibiotics: a study on the helical structure of the 2-9 sequence of emerimicins III and IV. *Proceedings of the National Academy of Sciences of the United States of America*, **1982**, 79, 7951-4	11.5	170
11	Linear oligopeptides. 81. Solid-state and solution conformation of homooligo(.alpha.-aminoisobutyric acids) from tripeptide to pentapeptide: evidence for a 310 helix. *Journal of the American Chemical Society*, **1982**, 104, 2437-2444	16.4	182
10	Linear oligopeptides. Part 85. Preferred conformations of linear homooligoprolines. N-tert-butyloxycarbonyl-D-prolyl-D-prolyl-L-proline. *Macromolecules*, **1982**, 15, 54-59	5.5	11
9	A hairpin-shaped peptide conformation stabilized by multiple intramolecular H-bonds for a linear alternating D,L hexapeptide. *Biochemical and Biophysical Research Communications*, **1982**, 107, 910-3	3.4	13

8	Conformational studies of peptides: Crystal and molecular structures of L-3,4-dehydroproline and its t-butoxycarbonyl and acetyl amide derivatives. *Biopolymers*, **1981**, 20, 283-302	2.2	12
7	Self-association of N-protected □-amino acids. Optically active and racemic N-tert-butyloxycarbonyl-alanine. *Biopolymers*, **1981**, 20, 1635-1649	2.2	16
6	Linear oligopeptides: 65?. Conformational analysis of the N-protected aromatic □-amino acid by X-ray diffraction and infrared absorption. *International Journal of Biological Macromolecules*, **1980**, 2, 217-224	7.9	20
5	Conformational of Diastereoisomeric Peptides. N-(tert-Butyloxycarbonyl)-L-prolyl-D-proline and Its Methyl Ester in the Solid State and in Solution. *Macromolecules*, **1980**, 13, 1454-1462	5.5	9
4	Conformational analysis of N-(tert.-amyloxycarbony-L-proline in the solid state and in solution. *International Journal of Peptide and Protein Research*, **1979**, 14, 130-42		25
3	Linear Oligopeptides. 59. Stereochemical Analysis ofN-tert-Butyloxycarbonyl-L-prolylsarcosine and N-tert-Butyloxycarbonylsarcosylsarcosine in the Solid State and in Solution. *Macromolecules*, **1979**, 12, 438-445	5.5	9
2	Structure and conformation of peptides: N-benzyloxycarboyl-(□ethyl)-L-glutamyl-(□ethyl)-L-glutamic acid ethyl ester. *Biopolymers*, **1979**, 18, 517-522	2.2	16
1	Solid-state and solution conformation of N-tert-butyloxycarbonyl-L-prolylglycine. *Macromolecules*, **1977**, 10, 1350-6	5.5	21